Prescription drug costs continue to be one of the biggest financial pressures facing retirees and older Americans. In fact, many Medicare beneficiaries (around 21%) spend more than $1,000 every year on medications for diabetes, cancer, heart disease, arthritis, and obesity. Now, Medicare drug negotiations are entering another major phase, with 15 additional medications expected to receive negotiated lower prices beginning in 2027. The latest list includes several blockbuster GLP-1 medications such as Ozempic, Wegovy, and Rybelsus, which have become some of the most talked-about weight-loss and diabetes treatments in the country.
